Comparative Pharmacology
Head-to-head clinical analysis: CETRORELIX ACETATE versus CETROTIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETRORELIX ACETATE versus CETROTIDE.
CETRORELIX ACETATE vs CETROTIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) antagonist. Competitively blocks GnRH receptors on pituitary gonadotropes, inhibiting secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. It competitively blocks GnRH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
250 mcg subcutaneously once daily, starting on day 7 of ovarian stimulation and continuing until the day of hCG administration. Alternatively, a single 3 mg subcutaneous dose on day 7 of stimulation if hCG is given on day 9.
0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of hCG administration.
None Documented
None Documented
Terminal elimination half-life: ~7-9 hours in healthy adults; prolonged to ~14-30 hours in patients with hepatic or renal impairment (clinical significance: no dose adjustment needed for mild-to-moderate renal or hepatic impairment, but caution in severe cases due to potential accumulation).
Terminal elimination half-life is approximately 36 hours after subcutaneous administration. This long half-life supports once-daily dosing for continuous GnRH antagonist effect.
Primarily renal (excreted unchanged in urine ~42% within 24 hours; total urinary recovery ~66-69% over 8 days); biliary/fecal elimination accounts for <5%.
Primarily renal excretion of unchanged drug (approx. 40-50%) and metabolites; remainder excreted in feces via biliary elimination. Total recovery in urine and feces accounts for >90% of dose.
Category C
Category C
GnRH antagonist
GnRH antagonist